A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

NCT00210470 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL: IRX-2
DRUG: Cyclophosphamide
DRUG: Indomethacin
DRUG: Zinc
DRUG: Omeprazole

Sponsor

Brooklyn ImmunoTherapeutics, LLC